Pfizer Zoloft mail-order expansion outpaces retail growth -- IMS data.
Executive Summary
PFIZER ZOLOFT 29% GROWTH IN MAIL-ORDER SCRIPTS is faster than the selective serotonin reuptake inhibitor's growth at the retail level, according to data presented by IMS America VP-Field Services Douglas Long at the American Managed Care Pharmacy Association's annual meeting Oct. 27 in San Antonio. Figures for the first half of 1996 indicate that Zoloft ranks fifth on a dollar basis in the retail setting, while the antidepressant is not among the top five in mail order.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth